Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 3Genitourinary 2Tumor-Agnostic 1Other solid neoplasm 1

Conditions

Prostatic Neoplasms 1Metastatic Castrate- Resistant Prostate Cancer 1

Interventions

Docetaxel 409pembrolizumab 332Prednisone 290enzalutamide 285Gemcitabine 274Radiotherapy 270Magnetic Resonance Spectroscopy 269Nivolumab 253Abiraterone Acetate 218Cisplatin 212Leuprolide 195Radiosurgery 192Sunitinib 188Carboplatin 161Androgen Antagonists 156bicalutamide 152Specimen Handling 149Goserelin 149Ipilimumab 131Paclitaxel 126acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 122apalutamide 118Cyclophosphamide 117Bevacizumab 116Sorafenib 114Everolimus 111abiraterone 108cabozantinib 105atezolizumab 105Biopsy 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
phenoxodiol × Genitourinary × Clear all
NCT03041285 2022-05-11

Idronoxil Suppository Combine With Radiotherapy for Metastatic Prostate Cancer

Royal North Shore Hospital

Phase 1 Terminated
1 enrolled
Genitourinary

Metastatic Castrate- Resistant Prostate Cancer

NCT00557037 2010-04-08

A Phase II Trial of Phenoxodiol in Patients With Castrate and Non-Castrate Prostate Cancer

MEI Pharma, Inc.

Phase 2 Completed
60 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡